BPI-43487 / Betta Pharma - LARVOL DELTA

Betta’s FGFR4 inhibitor approved for Phase I study in China (GBI Health) - "China-based Betta Pharmaceuticals Co., Ltd (300558.SZ) has announced a clinical trial nod from the National Medical Products Administration to initiate a Phase I clinical study for their drug candidate BPI-43487 in China. BPI-43487 is a potent and highly selective fibroblast growth factor receptor 4 (FGFR4) covalent non-reversible small molecule inhibitor under development to treat hepatocellular carcinoma and cholangiocarcinoma among other solid tumors with fibroblast growth factor 19 expansion."

Non-US regulatory • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor